Researcher
Stephane Steurbaut
- Keywords:Pharmacy and pharmacology, Medicine, General and logistic services
- Disciplines:Cardiology, Clinical pharmacy, Pharmacotherapy, Pharmaceutical care
Affiliations
- Clinical Pharmacology and Clinical Pharmacy (Research group)
Member
From1 Sep 2011 → Today - Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Jan 2021 → Today - Pharmaceutical and Pharmacological Sciences (Department)
Member
From8 Apr 2019 → Today - Faculty of Medicine and Pharmacy (Faculty)
Member
From22 Jun 2017 → 7 Sep 2017 - Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Pharmaceutical Chemistry, Drug Analysis and Drug Information (Department)
Member
From1 Oct 2012 → 31 Dec 2013 - Pharmaceutical Chemistry, Drug Analysis and Drug Information (Department)
Member
From1 Oct 2010 → 30 Nov 2012 - Pharmacology (Department)
Member
From1 Oct 2010 → 30 Sep 2012 - Clinical Pharmacology and Pharmacotherapy (Department)
Member
From1 Jan 2008 → 30 Jun 2019 - Studiebegeleidingscentrum (Administrative office)
Member
From12 Feb 2001 → 31 Dec 2001 - Pharmaceutical Biotechnology and Molecular Biology (Department)
Member
From1 Jan 1997 → 31 Dec 2006
Publications
11 - 20 of 49
- Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists(2023)
Authors: Maxim Grymonprez, Mirko Petrovic, Tine L M De Backer, M Arfan Ikram, Stephane Steurbaut, Lies Lahousse
- Interception of chronic medication discrepancies by the clinical pharmacist in the emergency department(2023)
Authors: Linde Van Cauwenberghe, Saskia Van Kemseke, Ellen Oudaert, Sofie Pauwels, Stephane Steurbaut, Ives Hubloue
Pages: 7-14 - Key elements in the quality assessment of a type 3 medication review(2023)
Authors: Anneleen Robberechts, Melissa Michielsen, Stephane Steurbaut, Guido R Y De Meyer, Hans De Loof
Pages: 1258364 - Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation(2023)
Authors: Maxim Grymonprez, Tine L M De Backer, Xander Bertels, Stephane Steurbaut, Lies Lahousse
- Perceptions of European students' representative associations about clinical pharmacy undergraduate education(2022)
Authors: Laura Moura, Rúben Viegas, Stephane Steurbaut, Filipa Alves da Costa
Pages: 944-953 - Adherence and persistence to oral anticoagulants in patients with atrial fibrillation(2022)
Authors: Maxim Grymonprez, Andreas Capiau, Stephane Steurbaut, Els Mehuys, Koen Boussery, Tine L M De Backer, Lies Lahousse
- European Society of Clinical Pharmacy definition of the term clinical pharmacy and its relationship to pharmaceutical care(2022)
Authors: Tobias Dreischulte, Bart Van Den Bemt, Stephane Steurbaut
Pages: 837-842 - Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Versus Warfarin in Patients with Atrial Fibrillation and (Morbid) Obesity or Low Body Weight(2022)
Authors: Maxim Grymonprez, Tine L M De Backer, Stephane Steurbaut, Koen Boussery, Lies Lahousse
Pages: 749-761 - Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018(2022)
Authors: Maxim Grymonprez, Cynthia Simoens, Stephane Steurbaut, Tine L M De Backer, Lies Lahousse
Pages: 887-898 - Impact of P-glycoprotein and/or CYP3A4-interacting drugs on effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation(2022)
Authors: Maxim Grymonprez, Kevin Vanspranghe, Andreas Capiau, Koen Boussery, Stephane Steurbaut, Lies Lahousse
Pages: 3039-3051